Fresh off yesterday's global medical response IPO right here at the New York Stock Exchange, it's clear that public markets remain highly receptive to scalable healthcare tech.
While Wall Street is actively rewarding companies that are pivoting to gentech AI to help tackle a massive crisis in the medical field, where physician burnout rates now top 50%, and the IPO window remains wide open and highly active right now, especially for scaled.
Cash generative companies will census healthcare went public back in 2018, but it's in the midst of a strategic pivot.
Joining me this morning to weigh in Joe Sardano, founder, chairman, and CEO of Sensus Healthcare.
Joe, good morning.
Great to have you here.
Thank you so much for joining me.
Thank you.
Well first and foremost, when it comes to the health care sector, this is something that we're watching in terms of performance on an annual basis, but we in on this.
Growing demand for innovative healthcare solutions right now.
Everybody's looking for some kind of solution that makes things better for their patients as well as for the hospital systems and the medical systems themselves.
Doctors in their particular practices require a lot of IT, a lot of AI.
It's going to help them become more productive, more profitable, and better service the patients that they serve as well.
So it's very, very important these days.
And here on FinTech TV we pay attention to what's happening with publicly traded companies, especially when it comes to the labor market, especially given the fact that AI is something that all of us are paying attention to.
But that burnout rate for physicians is also something that really stands out for us.
So why do the public markets remain so highly focused on investing right now in scalable healthcare tech?
I think it's important again to meet those needs and to provide those solutions for those physicians so that they don't exercise or they don't feel like they're overworked and things and it's not just the physicians, but it's also their staffs.
The staffs are very, very important to support the physicians to support the patients that come to those doctors, and if they don't help them become more productive and provide them with easier solutions to manage their everyday business solutions or problems, it's going to be very, very difficult for them.
Sustain the growth of patients that are coming into their realm these days and in 2026, all of us are paying attention to policy when it comes to health care.
So what's happening when it comes to reimbursement rates.
Well, we fortunately after a 15 years of effort in working with centers for Medicare and Medicaid Services have been awarded by Centers for Medicare and Medicaid Services a full reimbursement coding for our physicians.
Use with our technology and for the patients that they treat with skin cancer.
This is a very, very big opportunity for our company, for our technology, and for our physicians and the patients that we serve.
So we're very, very excited for this to have taken place January 1, and now we're in the field helping our physicians understand better what these codes mean for them and how it will make them more flexible and more opportunistic to treat the patients that they treat for skin cancer.
Skin cancer.
I understand there has been a surge in demand for treatment.
So tell us about some of the trends you're seeing right now.
Well, for about 60 years, the physicians and the patients had to rely on a single source to treat, and that was surgery.
They called it MS surgery and it was a technique that was developed by Dr.
Frederick Mose back in the 50s and 60s out of the University of Wisconsin and all it was was a technique to treat the skin cancer with a surgical procedure when 1 in 1500 patients. skin cancer.
Today the American Academy of Dermatology determines that 1 in 5 Americans will have skin cancer in their lifetime.
Currently there are 6 million people being treated each and every year, new cancers each and every year, basal cell and squamous cell.
There's a lot of pre-existing conditions that they cannot do surgery with, so superficial radiation therapy is the ideal solution and has become over the last 5 or 6 years, the number one non-surgical source for treating skin cancer.
And we can't deny the fact that people are living longer and given that there is more extreme weather, this is not a surprising statistic, but I do want to ask you when it comes to the dermatology space specifically what key metrics or innovations should investors.
Attention, they should be looking at the innovation and quite frankly, our superficial radiation therapy is the first technology that's come into this market space in the last 50-60 years.
In every other part of healthcare, and I've been in healthcare for over 45 years, bringing new solutions to the market.
It's the 1st 1st probably technology that they have that's coming into the space that's going to provide.
As good or better service than the surgery that's going to help doctors process more patients each and every day for skin cancer because right now we don't have a shortage of patients, we have a shortage of doctors.
And finally, before I let you go, it is indeed a crowded sector.
So what gives census a competitive advantage right now we're the only company that offers this technology to our doctors.
There's nobody else in the.
In the world that offers this type of technology that gives the doctors the best solution for their patients in treating their patients and providing up to a 99% cure rate.
So this is great for the doctors and also great for the patients.
And last but not least, before I let you go, we all know that the summer driving season is right around the corner, but that also means Memorial Day is coming up.
So hindsight is always 2.
When it comes to skin protection as well as skin cancer, what should viewers out there be paying attention to?
Wear your sunscreen and wear it is the strongest that you can get.
Apply it off, make sure it's water resistant, but wear your sunscreen, stay out of the sun, cover yourself with hats, long sleeves, all of those things.
Well, thank you so much for joining us today, Joe, and I appreciate all of your insights as well as your perspective.
Thank you very much.
Pleasure.
